- Home
- DSX vs PBYI Comparison
DSX vs PBYI Comparison
Compare DSX & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSX
- PBYI
- Stock Information
- Founded
- DSX 1999
- PBYI 2010
- Country
- DSX Greece
- PBYI United States
- Employees
- DSX N/A
- PBYI 172
- Industry
- DSX Marine Transportation
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- DSX Consumer Discretionary
- PBYI Health Care
- Exchange
- DSX Nasdaq
- PBYI Nasdaq
- Market Cap
- DSX 172.5M
- PBYI 175.7M
- IPO Year
- DSX 2005
- PBYI N/A
- Fundamental
- Price
- DSX $1.64
- PBYI $3.45
- Analyst Decision
- DSX
- PBYI Strong Buy
- Analyst Count
- DSX 0
- PBYI 1
- Target Price
- DSX N/A
- PBYI $7.00
- AVG Volume (30 Days)
- DSX 274.6K
- PBYI 314.4K
- Earning Date
- DSX 07-30-2025
- PBYI 07-31-2025
- Dividend Yield
- DSX 2.44%
- PBYI N/A
- EPS Growth
- DSX N/A
- PBYI 143.51
- EPS
- DSX 0.05
- PBYI 0.77
- Revenue
- DSX $225,498,000.00
- PBYI $232,709,000.00
- Revenue This Year
- DSX N/A
- PBYI N/A
- Revenue Next Year
- DSX $12.09
- PBYI N/A
- P/E Ratio
- DSX $30.69
- PBYI $4.48
- Revenue Growth
- DSX N/A
- PBYI 2.68
- 52 Week Low
- DSX $1.27
- PBYI $2.23
- 52 Week High
- DSX $2.86
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- DSX 57.85
- PBYI 50.36
- Support Level
- DSX $1.48
- PBYI $3.26
- Resistance Level
- DSX $1.54
- PBYI $3.68
- Average True Range (ATR)
- DSX 0.05
- PBYI 0.12
- MACD
- DSX 0.00
- PBYI -0.01
- Stochastic Oscillator
- DSX 88.89
- PBYI 46.51
About DSX Diana Shipping inc. common stock
Diana Shipping Inc provides shipping transportation services. The company, through its subsidiaries, operates a fleet of vessels consisting of dry bulk carriers such as Panamax, Kamsarmax, Post-Panamax, Capesize and Newcastlemax vessels. Using this fleet, the firm provides transportation services for various goods including coal, iron ore, and grains. It also transports minor bulks, including steel products, cement, and fertilizers through its dry bulk carrier vessels. The operation of the vessels is the main source of revenue generation, the services provided by the vessels are similar and all operate under the same economic environment.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.